Stem Cells/Wnt

AP-C3 is a selective inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), exhibiting a pIC50 of 6.3. This compound demonstrates limited inhibition of cGKII-dependent anion secretion, making it a valuable tool for studying cGKII signaling pathways. AP-C3 is applicable in research focused on cardiovascular and gastrointestinal functions mediated by cGKII.

AP-C6 is a selective inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), demonstrating a pIC50 of 6.5. This compound effectively inhibits human cGKII activity in a concentration-dependent manner in vitro. Additionally, AP-C6 enhances cAMP signaling through phosphodiesterase (PDE) inhibition, making it a valuable tool for research involving cGKII and related signaling pathways.

AP-C7 is a selective inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), exhibiting a pIC50 value of 5.0. This compound demonstrates weak inhibition of cGKII-dependent anion secretion, making it a valuable tool for exploring the role of cGKII in cellular signaling pathways and its impact on various physiological processes. AP-C7 can be utilized in research focused on cardiovascular biology, gastrointestinal function, and related areas studying cGMP signaling mechanisms.

AP-C1 is a selective inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), demonstrating a pIC50 of 6.5. This compound primarily attenuates cGKII activity while displaying minimal effects on cGKII-mediated anion secretion. AP-C1 is valuable for research applications focused on investigating the role of cGKII in cellular signaling and related physiological processes.

AP-C4 is a selective inhibitor of guanosine 3′,5′-cyclic monophosphate (cGMP)-dependent protein kinase II (cGKII), exhibiting a pIC50 value of 5.2. This compound demonstrates the ability to effectively inhibit cGKII without affecting cGKII-dependent anion secretion. AP-C4 is valuable for research examining the role of cGKII in various physiological and pathological processes, enabling further exploration of cGKII's functions in signaling pathways.

1-NH2-cGMP is an analog of cyclic guanosine monophosphate (cGMP), designed to serve as a potent signaling molecule in various biological systems. This compound exhibits activity in modulating nitric oxide signaling pathways and influencing smooth muscle relaxation. 1-NH2-cGMP is applicable in research exploring cardiovascular function, neuronal signaling, and cellular proliferation, making it a valuable tool for studies involving cGMP-dependent signaling mechanisms.

8-Br-PET-cGMP is a selective agonist of cGMP-dependent protein kinase type I (cGKI). It facilitates the dimerization of cGKI, enhancing its catalytic activity through binding to the regulatory domain. This compound is valuable for investigating cGMP signaling pathways involved in cellular processes such as growth, vasodilation, and the functionality of smooth muscle cells.

PET-cGMP is a cyclic guanosine monophosphate analog that selectively activates protein kinase G (PKG) I, with an EC50 of 3.8 nM for the PKG Iβ isoform and 193 nM for PKG II. Its potent agonistic properties make it a valuable tool in studying signaling pathways involving PKG I, particularly in cardiovascular and neuronal research. Researchers can utilize PET-cGMP to elucidate the roles of cGMP signaling in various physiological and pathological contexts.

Sp-8-pCPT-PET-cGMPS is a selective activator of PKG-I (protein kinase G I). This compound has demonstrated pivotal biological activity by facilitating NO/NOS/sGC/PKG-I signaling pathways, making it an invaluable tool for research in cardiac differentiation. Its ability to modulate these pathways contributes to a deeper understanding of cardiovascular biology and potential therapeutic interventions.

8-Br-cGMP-AM is a potent activator of cGMP-dependent protein kinase (PKG). This compound induces various biological effects, including vasodilation and inhibition of platelet aggregation. Its ability to modulate cardiovascular responses makes it a valuable tool in the study of cardiovascular diseases and related physiological processes.

Sp-cGMPS is an activator of cGMP-dependent protein kinases (PKGs), which play a crucial role in signal transduction pathways. This compound enhances PKG activity, making it valuable for studying various physiological processes and pathologies. Its application is particularly relevant in cardiovascular disease research, where modulation of PKG activity can influence vascular function and cardiomyocyte signaling.

Rp-8-pCPT-cGMPS is a competitive inhibitor of cGMP-dependent protein kinase (PKG) with a Ki value of 0.5 μM. Its high lipid solubility facilitates cellular penetration, enabling effective inhibition of PKG activity within cells. This reagent is valuable for investigating the role and function of PKG in cellular processes, particularly in platelets.

Sp-8-Br-PET-cGMPS is a membrane-permeable agonist of protein kinase G (PKG), effectively activating cGMP-dependent protein kinases I α and I β. This compound is also a selective inhibitor of retinal-type cGMP-gated ion channels and exhibits resistance to mammalian cyclic nucleotide-dependent phosphodiesterases. Its enhanced lipophilicity and permeability compared to Sp-8-pCPT-cGMPS make it a valuable tool for investigating cGMP signaling pathways in neurological research.

SGK1-IN-8 is a potent inhibitor of SGK1 and GSK3β, exhibiting an IC50 of 0.11 μM against human SGK1 and 3.39 μM against human GSK3β. This compound effectively inhibits the catalytic activities of both SGK1 and GSK3β, leading to a reduction in the phosphorylation of the TAU protein at the Ser214 site. SGK1-IN-8 is utilized in research focused on Alzheimer's disease and related neurodegenerative disorders.